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Agonist-induced changes in the phosphorylation of the myosin-
binding subunit of myosin light chain phosphatase and CPI17, two
regulatory factors of myosin light chain phosphatase, in smooth muscle
Naohisa NIIRO, Yasuhiko KOGA and Mitsuo IKEBE1
Department of Physiology, University of Massachusetts Medical School, Worcester, MA 01655, U.S.A.
The inhibition of myosin light chain phosphatase (MLCP)
enhances smooth muscle contraction at a constant [Ca#+]. There
are two components, myosin-binding subunit of MLCP (MBS)
and CPI17, thought to be responsible for the inhibition of MLCP
by external stimuli. The phosphorylation of MBS at Thr-641 and
of CPI17 at Thr-38 inhibits the MLCP activity in itro. Here we
determined the changes in the phosphorylation of MBS and
CPI17 after agonist stimulation in intact as well as permeabilized
smooth muscle strips using phosphorylation-site-specific anti-
bodies as probes. The CPI17 phosphorylation transiently
increased after agonist stimulation in both a-toxin skinned and
intact fibres. The time course of the increase in CPI17
phosphorylation after stimulation correlated with the increase in
myosin regulatory light chain (MLC) phosphorylation. The
increase in CPI17 phosphorylation was significantly diminished
by Y27632, a Rho kinase inhibitor, and GF109203x, a protein
kinase C inhibitor, suggesting that both the protein kinase C and
INTRODUCTION
It is known that phosphorylation of the regulatory light chain of
smooth muscle and non-muscle myosin II [myosin regulatory
light chain (MLC)] at Ser-19 is required for the activation
of actomyosin contractile activity. Therefore the regulation of
myosin II phosphorylation is a critical determinant of contraction
of diverse cell contractile events. The best-characterized cell type
is the smooth muscle cell, and evidence indicates that myosin
phosphorylation in smooth muscle is regulated by two processes,
i.e. a Ca#+-dependent process and a Ca#+-independent process.
While several protein kinases can phosphorylate smooth
muscle myosin [1–4], it is thought that myosin light chain kinase
(MLCK), a Ca#+}calmodulin-dependent MLC-specific protein
kinase, is primarily responsible for the phosphorylation of myosin
in smooth muscle [1–4], since an increase in cytosolic Ca#+
concentration induces MLC phosphorylation in smooth muscle
tissues [1,2,4]. On the other hand, it was realized that the force
development of smooth muscle is not simply determined by
cytoplasmic [Ca#+] [5–8]. For a given [Ca#+], a higher force is
achieved by agonist-induced stimulation than by depolarization-
induced contraction. Using permeabilized smooth muscle strips
having intact receptor-coupled systems, it was shown that an
agonist can increase the force developed by smooth muscle even
when cytoplasmic [Ca#+] was clamped [9,10]. This agonist-
Abbreviations used: DTT, dithiothreitol ; ET-1, endothelin-1 ; GDP[b-S], guanosine 5«-[b-thio]diphosphate ; GTP[S], guanosine 5«-[c-thio]triphosphate ;
MBS, myosin-binding subunit of myosin light chain phosphatase ; MLC, myosin regulatory light chain ; MLCK, myosin light chain kinase ; MLCP, myosin
light chain phosphatase ; PDBu, phorbol 12,13-dibutyrate ; PKC, protein kinase C; b-ME, b-mercaptoethanol ; PSS, physiological saline solution.
1 To whom correspondence should be addressed (e-mail Mitsuo.Ikebe!umassmed.edu).
Rho kinase pathways influence the change in CPI17
phosphorylation. On the other hand, a significant level of
MBS phosphorylation at Thr-641, an inhibitory site, was ob-
served in the resting state for both skinned and intact fibres
and the agonist stimulation did not significantly alter the
MBS phosphorylation level at Thr-641. While the removal of
the agonist markedly decreased MLC phosphorylation and
induced relaxation, the phosphorylation of MBS was un-
changed, while CPI17 phosphorylation markedly diminished.
These results strongly suggest that the phosphorylation of
CPI17 plays a more significant role in the agonist-induced in-
crease in myosin phosphorylation and contraction of smooth
muscle than MBS phosphorylation in the Ca#+-independent
activation mechanism of smooth muscle contraction.
Key words: histamine, myosin phosphorylation, protein kinase
C, Rho-associated kinase, smooth muscle contraction.
induced ‘Ca#+ sensitization’ indicates that there is an additional
mechanism that can regulate smooth muscle contractile mach-
inery. Subsequently, it was shown that the increase in force
elicited by an agonist at a given Ca#+ is due to the inhibition of
myosin light chain phosphatase (MLCP) [10,11]. The possible
mechanism by which agonists inhibit MLCP activity appears to
be G-protein coupled, because guanosine 5«-[c-thio]triphosphate
(GTP[S]), an activator of G-protein, inhibits myosin
dephosphorylating activity in permeabilized smooth muscle strips
[9,10,12].
Activation of heterotrimeric G-proteins would activate the
phosphatidylinositol cascade, thus producing diacylglycerol and
Ins(1,4,5)P
$
. Protein kinase C (PKC), which is activated by
diacylglycerol, has been suggested to play a role in the regulation
of myosin dephosphorylation [13,14]. Recently, it was suggested
that PKC mediated inhibition of MLCP via activation of the
MLCP inhibitor, CPI17 (where CPI is PKC-activated protein
phosphatase inhibitor) [15], whose inhibitory activity requires
the phosphorylation at Thr-38 by PKC [16]. It was shown
that the addition of the phosphorylated CPI17 enhances the
force of the permeabilized smooth muscle fibre [17]. Recently, it
was shown that the phosphorylation of CPI17 is actually in-
creased in smooth muscle fibres after agonist stimulation [18].
The Ras-family small G-protein, Rho, has been found to be
involved in smooth muscle stimulation–contraction coupling, as
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first reported by Takai and his collaborators [19]. They found
that epidermal differentiation inhibitor (EDIN) and exoenzyme
C3 from Clostridium botulinum, both of which are known to
ADP-ribosylate the Rho p21 family thus inactivating Rho
activity, abolish GTP[S]-enhanced Ca#+ sensitization of skinned
mesenteric arterial smooth muscle. Similar results have been
reported by other investigators [20–22]. Supporting this hypo-
thesis, Otto et al. [23] reported that the addition of the
constitutively active mutant of RhoA to b-escin-permeabilized
smooth muscle enhanced the carbachol-induced increase in Ca#+
sensitivity of force production.
MLCP consists of three subunits, a large myosin-binding sub-
unit of MLCP (MBS), a 20 kDa small subunit and a catalytic
subunit of the type 1 protein serine}threonine phosphatase
family [24–26]. It has been shown that MBS can be
phosphorylated by Rho-dependent kinase, resulting in a decrease
in MLCP activity in itro [27]. Rho kinase phosphorylates MBS
at two sites in itro, i.e. Thr-641 and Thr-799 (in the rat
MBS sequence, corresponding to Thr-695 and Thr-850 in chicken
M133, respectively), of which Thr-641 is responsible for the
inhibition of MLCP activity [28]. This raises the hypothesis that
activation of the Rho signalling pathway could phosphorylate
MBS by Rho kinase, thus down-regulating MLCP and increasing
contraction. Consistent with this idea, it was shown recently that
GTP[S] increased the phosphorylation of MBS in permeabilized
strips [29] or cultured smooth muscle cells [30]. However, since
MBS can be phosphorylated at multiple sites by protein kinases
and the site responsible for the inhibition of MLCP activity is
Thr-641, an important question is whether the phosphorylation
site critical for the regulation of MLCP significantly changes
during agonist-induced stimulation of smooth muscle contrac-
tion.
In the present study, we examined the changes in MBS
phosphorylation at Thr-641 and CPI17 phosphorylation at Thr-
38 along with the change in MLC phosphorylation at Ser-19 in
intact as well as a-toxin-permeabilized smooth muscle strips
during the contraction–relaxation process by using
phosphorylation-site-specific antibodies as probes.
EXPERIMENTAL
Proteins
Smooth muscle MLC was expressed in Escherichia coli and
purified as described [31,32]. The cDNA clone of human Rho
kinase (ROCKII) was kindly supplied by Dr T. Leung (University
of Singapore). Rat MBS cDNA was supplied by Professor P.
Cohen (University of Dundee, Dundee, U.K.). The cDNAs of
rabbit PKCa and e were supplied by Dr S. Ohno (Yokohama
City University, Yokohama, Japan). The cDNAs containing
entire coding region were subcloned into pFastbacHT
(Invitrogen, Carlsbad, CA, U.S.A.) baculovirus transfer vector
at the poly-linker region downstream of the hexa-histidine tag.
Recombinant viruses were produced according to manufacturer’s
procedures.
To express recombinant PKCs and Rho kinase, Sf9 cells were
infected with each viral stock and cultured at 28 °C for 72 h.
Harvested Sf9 cells were lysed by sonication in 15 ml of buffer A
[0.15 M NaCl, 30 mM Tris}HCl, pH 8.0, 2 mM b-mercapto-
ethanol (b-ME), 2 mM PMSF, 10% (v}v) glycerol, 0.05%
Triton X-100, 10 lg}ml leupeptin and 0.1 mg}ml trypsin in-
hibitor] for PKC purification, or buffer B [0.5 M NaCl, 30 mM
Tris}HCl, pH 8.0, 2 mM b-ME, 2 mM PMSF, 10% glycerol,
0.5% Triton X-100 and 10 lg}ml leupeptin] for Rho kinase
purification. After centrifugation at 10000 g for 20 min at 4 °C,
the supernatants were mixed with Ni#+-nitrilotriacetic acid–
agarose (Qiagen) on a rotating wheel for 30 min at 4 °C. The
resin suspensions were loaded on a column (1 cm‹10 cm) and
washed with 10 bed volumes of washing buffer (0.15 M NaCl,
5 mM imidazole}HCl, pH 8.0, 10% glycerol and 2 mM b-ME).
PKCs or Rho kinase was eluted with elution buffer (0.15 M
NaCl, 0.25 M imidazole}HCl, pH 8.0, 10% glycerol and 2 mM
b-ME). After SDS}PAGE analysis, the fractions containing
PKCs or Rho kinase were pooled and dialysed against 150 mM
NaCl, 30 mM Tris}HCl, pH 7.5 and 1 mM dithiothreitol (DTT).
Rat MBS was purified by the same procedure as described above.
The DNA fragment corresponding to the coding region of
mouse CPI17 cDNA was supplied by Dr M. Eto (University of
Virginia, Charlotteville, VA, U.S.A.) and amplified by PCR
using the primers 5«-GAAGGAGATATACccatggCTGCGC-
AG-3« and 5«-GGAGCTCgaattcTCAGGGTGGGGCAGTG-
3«, to introduce restriction sites for NcoI and EcoRI shown by
lower-case letters (the initiation and termination codons are
indicated by underlines). The 0.45 kb NcoI–EcoRI fragment was
cloned into pET-30 plasmid (Novagen). The constructed plasmid
encoded the 44 residues of tag sequence containing (His)
’
segment
at the N-terminal side of CPI17. Escherichia coli BL21(DE3)
cells were transformed with this plasmid and the transformed cells
were grown in LB media at 37 °C until the attenuance at 600 nm
reached 0.6. Protein expression was induced by the addition of
0.1 mM isopropyl b-d-thiogalactoside for 3 h at 37 °C. Cells
were collected and lysed in 0.5 M NaCl, 20 mM potassium
phosphate, pH 7.0, 1 mM benzamidine, 10 mM imidazole}HCl
and 0.1 mM PMSF. The lysate was heated at 90 °C for 5 min and
clarified by centrifugation at 22000 g for 20 min at 4 °C.
Hexahistidine-tagged CPI17 was absorbed to Ni#+-nitrilotriacetic
acid–agarose, and bound proteins were eluted with 500 mM
imidazole}HCl, pH 7.0. Protein concentrations were determined
by densitometric tracing of the protein bands stained with
Coomassie Brilliant Blue on an SDS}polyacrylamide gel
with BSA as a standard.
Production of antibodies
Peptides Cys-Ser-Lys-Leu-Gln-Ser-Pro-Ser-Arg-Ala-Arg-Gly-
Pro-Gly-Gly-Ser-Pro-Gly-Gly-Leu-Gln-Lys-Arg-His-Ala-Arg
(corresponding to amino acids 12–36 of CPI17), Cys-Arg-His-
Ala-Arg-Val-phosphoThr-Val-Lys-Tyr-Asp-Arg (amino acids
33–43 of CPI17), Cys-Gln-Ser-Arg-Arg-Ser-phosphoThr-Gln-
Gly-Val-Thr-Leu (amino acids 636–646 of rat MBS) and
Cys-Glu-Lys-Arg-Arg-Ser-phosphoThr-Gly-Val-Ser-Phe-Trp
(amino acids 694–704 of rat MBS) were chemically synthesized
as antigens by Genemed Synthesis (South San Francisco, CA,
U.S.A.), as well as the dephosphorylated forms of the peptides
necessary for the antibody purification. An N-terminal cysteine
was added to the peptide for the purpose of conjugation with
keyhole limpet haemocyanin. Antibodies were prepared by
injecting two rabbits with keyhole limpet haemocyanin-coupled
peptide. Phosphorylation-site-specific antibodies against MBS
and CPI17 were purified by two-step chromatography: affinity
chromatography on phosphopeptide-coupled resin and then
absorption in dephosphorylated peptide-coupled resin. Anti-
CPI17 antibody, raised against the peptide corresponding to
amino acids 12–36 of CPI17, recognized CPI17 regardless of the
phosphorylation state and was affinity purified by peptide-
coupled affinity chromatography.
Affinity resins were prepared by cross-linking the synthesized
peptides to epoxyamino hexyl (‘EAH’)-Sepharose 4B
(Amersham Biosciences) in the presence of sulpho-SMCC
(Pierce). Anti-phosphorylated MLC mouse monoclonal antibody
was produced as described previously [33]. Anti-MBS antibodies
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Figure 1 Specificity of phosphorylation-site-specific antibodies
(A) Relationship between the amounts of samples and density of Western blot for MBS. MBS was phosphorylated by Rho kinase as described in the Experimental section. Different amounts of
phosphorylated MBS indicated above the panel were subjected to SDS/PAGE followed by Western blot using anti-pThr-641 and anti-pThr-799 antibodies as probes. Blots were quantitated by
densitometry and the relative intensities were plotted as a function of the amount of MBS. All values are expressed as means‡S.E.M. (n fl 4). D, anti-pThr-641 ; *, anti-pThr-799. (B)
Dephosphorylated (lane 1) and phosphorylated (lane 2) wild-type MBS, and Thr-641Ala (lane 3), and Thr-799Ala (lane 4) mutant MBS phosphorylated by Rho kinase were subjected to Western
blot using anti-pThr-641, anti-pThr-799 and anti-MBS antibodies. 20 ng of MBS was loaded into each lane. (C) Relationship between the amount of samples and density of Western blot for CPI17.
Mouse CPI17 was phosphorylated by PKCa as described in the text. Different amounts of phosphorylated CPI17 indicated above the panel were subjected to SDS/PAGE followed by Western blot
using anti-pThr-38 antibodies as probes. Blots were quantitated by densitometry and the relative intensities were plotted as a function of the amount of CPI17. All values are expressed as
means‡S.E.M. (n fl 4). (D) Dephosphorylated (lane 1) and phosphorylated (lane 2) wild-type CPI17 and Thr-38Ala mutant CPI17 (lane 3) phosphorylated by PKCa were subjected to Western
blot using anti-pThr-38 antibodies. 1 ng of CPI17 was loaded into each lane.
that recognize both phosphorylated and dephosphorylated forms
were obtained from BABCO.
Biochemical procedures
MBS was phosphorylated by Rho kinase in 20 mM Tris}HCl,
pH 7.5, 4 mM MgCl
#
, 35 mM NaCl, 1 mM EGTA, 0.5 mM
DTT, 0.2 lM microcystin-LR, 3 lg}ml Rho kinase, 25 lg}ml
MBS and 0.1 mM ATP at 25 °C for a period indicated. CPI17
was phosphorylated by PKCa in 30 mM Tris}HCl, pH 7.5,
2 mM MgCl
#
, 50 mM NaCl, 0.2 mM CaCl
#
, 1 mM DTT, 1 lM
microcystin-LR, 50 ng}ml phorbol 12,13-dibutyrate (PDBu),
0.1 mg}ml phosphatidylserine, 3 lg}ml PKC and 0.1 mM ATP
at 25 °C. SDS}PAGE was carried out on a 5–20% poly-
acrylamide gradient slab gel using the discontinuous buffer
system of Laemmli [34]. Western blotting was carried out as
described previously [35].
Force measurement and myosin light chain phosphorylation of
rabbit femoral artery
New Zealand White rabbits (2.5–3.0 kg) were killed by the
injection of pentobarbital (100 mg}kg). Smooth muscle strips
were dissected from the femoral arteries and placed in physio-
logical saline solution (PSS) consisting of the following: 137 mM
NaCl, 5.4 mM KCl, 23.8 mM NaHCO
$
, 1.5 mM CaCl
#
,
1 mM MgCl
#
and 5.5 mM d-glucose. Fat and adventitia were
removed mechanically under a binocular microscope, and
endothelium was removed by gentle rubbing with a cotton swab.
Arteries were then cut into strips (5 lm thick, 750 lm wide
and 3 mm long), and the smooth muscle strips were permeabil-
ized with a-toxin (5000 units}ml) in relaxing solution for 60 min
at room temperature and then treated with A23187 for 15 min to
deplete the sarcoplasmic reticulum Ca#+. The strips were tied
with silk filaments and suspended between the fine tips of two
tungsten needles, one of which was connected to a force trans-
ducer (FORT-10; World Precision Instruments, Sarasota, FL,
U.S.A.). The standard relaxing solution used for resting states
of the permeabilized strips contained the following: 100 mM po-
tassium methanesulphonate, 5.9 mM MgCl
#
, 5.0 mM Na
#
ATP,
10 mM EGTA, 10 mM creatine phosphate and 50 mM Tris}
maleate, pH 6.8. In the activating solution, a calculated amount
of calcium methanesulphonate was added to give the final
desired concentration of free Ca#+ ions. All solutions were
adjusted to pH 6.8 at 25 °C and the developed tension was
expressed as a percentage, assigning the respective values in
relaxing solution and in the steady state of 10 lM Ca#+-induced
contraction, recorded at the end of experiment, to be 0% and
100%.
For the contractility measurement of intact smooth muscle,
each strip was mounted vertically in normal PSS, which was
maintained at 37 °C and pH 7.4 bubbled with 95% O
#
}5% CO
#
.
The lower end of the strip was fixed by a small clip, and the upper
end of the strip was attached by a small clip and thread to a force
transducer to record the isometric tension. The strips were
stimulated with 118 mM K+ PSS, which was identical with
normal PSS except for an equimolar substitution of KCl for
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NaCl, at 15 min intervals until the developed tension reached
a maximum. After recording the responsiveness to 118 mM K+
PSS, each strip was stimulated with a contractile agonist
[histamine or endothelin-1 (ET-1)] in normal PSS.
The phosphorylation of MLC, MBS and CPI17 in smooth
muscle strips was determined as follows. The contractile
responses were terminated by immersing the strips in dry-ice-
cold acetone containing 10% trichloroacetic acid and 10 mM
DTT. Smooth muscle strips were homogenized in ice-cold acetone
containing 10% trichloroacetic acid and 10 mM DTT using a
hand-operated glass-to-glass homogenizer. The homogenate was
centrifuged at 10000 g and 4 °C for 5 min and the supernatent
was carefully removed. The pellet was washed with ice-cold
acetone containing 10 mM DTT three times, and after the third
wash the remaining acetone was allowed to completely evaporate
for 15 min on ice. Proteins were solubilized by sonication in
buffer containing 100 mM Tris}HCl, pH 6.8, 1% SDS, 50 mM
DTT, 15% glycerol and 0.002% Bromophenol Blue and then
boiled for 5 min. The sample was subjected to SDS}PAGE,
followed by immunoblot using various antibodies.
Statistical analysis
The results are expressed as means‡S.E.M. ANOVA was
performed to evaluate the global statistical significance, and
when a significant F value was found, the Scheffe post hoc test
was performed to identify the difference among the groups.
Values were considered significantly different at P! 0.05.
RESULTS
Specificity of the phosphorylation-site-specific antibodies of MBS
and CPI17
To monitor the change in the phosphorylation of MBS of
MLCP, CPI17 and the MLC in smooth muscle fibre, we produced
various phosphorylation-site-specific antibodies. It has been
shown that MBS is phosphorylated by Rho kinase and that the
major phosphorylation sites are Thr-641 and Thr-791 [28], of
which the former site is responsible for the inhibition of MLCP
in itro. On the other hand, Thr-38 is the major phosphorylation
site of CPI17, and the phosphorylation at this site significantly
enhances the inhibitory activity of CPI17 against MLCP [16].
Rat MBS was expressed in Sf9 cells and purified as described in
the Experimental section. The purified MBS was phosphorylated
by Rho kinase to a stoichiometric ratio of approx. 2 mol of
phosphate}mol of MBS. Figures 1(A) and 1(B) shows the
Western blot of the phosphorylated MBS. Both phosphorylation-
specific antibodies, anti-pThr-641 and anti-pThr-799, recognized
MBS phosphorylated by Rho kinase but not its un-
phosphorylated form, indicating that these antibodies are specific
to the phosphorylated MBS (Figure 1B). To further ensure the
specificity of the antibodies for the responsible epitopes, we
produced mutant MBS in which the phosphorylatable Thr
residues are mutated to Ala (Thr-641Ala and Thr-799Ala). Anti-
pThr-641 antibodies failed to recognize Thr-641Ala MBS even
after phosphorylation by Rho kinase, while it recognized the
phosphorylated Thr-799Ala mutant. On the other hand, anti-
pThr-799 antibodies did not react with the phosphorylated Thr-
799Ala mutant, but reacted with Thr-641Ala mutant (Figure 1B).
These results clearly demonstrated that these antibodies
specifically recognize the phosphorylated MBS at Thr-641 and
Thr-799, respectively. On the other hand, anti-MBS antibodies
recognized MBS regardless of its phosphorylation state (Figure
1B).
Figure 2 Histamine-induced activation of the contraction of an a-toxin-
permeabilized strip of rabbit femoral artery
(A) Representative trace of histamine-induced activation of contraction at constant [Ca2+] in a-
toxin-permeabilized rabbit femoral artery. Histamine (10 lM) was added at the steady state of
the contraction at pCa 7. A Rho kinase inhibitor, Y27632 (10 lM), was added when the
histamine-induced sensitization reached steady state. The addition of GDP-[b-S] further
diminished the contraction to a level similar to that before the addition of histamine. (B) Effect
of Y27632 (10 lM) and a PKC inhibitor, GF109203x (5 lM), on the histamine-stimulated
activation of contraction at pCa 7 in a-toxin-permeabilized rabbit femoral artery. Inhibitors were
applied 5 min before the addition of histamine. Grey bars and black bars indicate Ca2+ (pCa
7)-induced contraction and histamine-stimulated activation, respectively. Values are
means‡S.E.M. from more than four independent experiments and are expressed as
percentages of the maximum contraction obtained at pCa 5. *P ! 0.05, **P ! 0.01.
Figures 1(C) and 1(D) show the Western blot of CPI17 with
anti-CPI17 antibodies. CPI17 phosphorylated by PKC (1.0 mol
of phosphate}mol of CPI17) as well as its unphosphorylated
form were subjected to Western blot analysis. Anti-phospho-
CPI17 (anti-pThr-38) antibodies recognized the phosphoryl-
ated CPI17, but not its unphosphorylated form. Furthermore,
anti-pThr-38 did not recognize Thr-38Ala CPI17 incubated with
PKC for phosphorylation. These results demonstrated that anti-
pThr-38 is specific to the phosphorylated Thr-38 of CPI17. For
all three phosphorylation-site-specific antibodies tested, the signal
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Figure 3 Change in the phosphorylation of MLC, MBS and CPI17 during the histamine-induced contraction of a-toxin-permeabilized rabbit femoral artery
(A) Smooth muscle strips incubated for 5 min in pCa 7 alone (lane 1) or with 10 lM histamine (lanes 2–4, 1, 3 and 5 min after histamine stimulation, respectively), 10 lM histamine plus 10 lM
Y27632 (lane 5) or 10 lM histamine plus 5 lM GF109203x (lane 6) were homogenized and subjected to Western blot using anti-pThr-641, anti-pThr-799, anti-MBS, anti-pThr-38, anti-CPI17,
anti-pMLC and anti-MLC antibodies. (B) Quantitative analysis of Western blot. Bands of the Western blot were compared densitometrically and expressed as percentages of the value from the
histamine-stimulated rabbit femoral artery. White bars, before histamine stimulation ; black bars, 5 min after histamine stimulation ; grey bars, 5 min after histamine stimulation in the presence of
10 lM Y27632 ; hatched bars, 5 min after histamine stimulation in the presence of 5 lM GF109203x. Data represent the means‡S.E.M. from more than four independent experiments. *P ! 0.05,
**P ! 0.01, ***P ! 0.001. (C) Representative images of Western blot showing temporal changes in the phosphorylation level of CPI17 and MLC. Permeabilized smooth muscle strips were stimulated
with 10 lM histamine at pCa 7. Contractile responses were terminated at the various times indicated and then homogenates of the muscle strips were subjected to SDS/PAGE and Western blot
analysis. (D) Quantitative analysis of temporal changes in the phosphorylation of CPI17 at Thr-38 and MLC. Relative phosphorylation levels of CPI17 at Thr-38 (D) and MLC (E) are indicated
as ratios (anti-pThr-38/anti-CPI17 and anti-pMLC/anti-MLC, respectively) of the bands in the Western blot. Each value represents the mean‡S.E.M. from more than three independent experiments
and indicated as a percentage of the values at 5 min after histamine stimulation.
intensity of the blots showed a linear relationship with the
amount of phosphorylated proteins loaded on to the gel (Figures
1A and 1C). The intensities of Western blot bands obtained from
the smooth muscle strips fell in the linear portion of the curves.
Agonist-induced change in the phosphorylation of MBS and CPI17
in permeabilized smooth muscle strips
To investigate the role of CPI17 and MBS phosphorylation
in the agonist-induced changes in myosin phosphorylation and
smooth muscle contraction, we utilized a-toxin-permeabil-
ized smooth muscle strips. It is known that a-toxin treatment
produces small holes in the plasma membrane, thus allowing
passage of only small-molecular-mass substances, not large-
molecular-mass cellular components such as proteins. Further-
more, a-toxin treatment does not disturb agonist-induced
signalling systems [9,10]. Figure 2 shows the typical force traces
of a-toxin-permeabilized rabbit femoral artery smooth muscle
strips. At pCa 7, a minimum level of force was developed that
was markedly augmented by 10 lM histamine at constant Ca#+
(Figures 2A and 2B). The phosphorylation level of MLC was
monitored by using anti-pMLC specific antibody that recognizes
the phosphorylated Ser-19 of the regulatory light chain [33]. The
strips were quickly immersed in trichloroacetic acid}acetone at
various times after histamine stimulation to quench the reaction.
The strips were then subjected to Western blot analysis.
Phosphorylation of MLC probed by anti-pMLC-specific anti-
body at pCa 7 was significantly increased by histamine (Figures
3A and 3B). CPI17 phosphorylation was negligible before
histamine stimulation at pCa 7, but the phosphorylation mark-
edly increased after histamine treatment in a-toxin-permeabilized
fibres (Figures 3A and 3B). On the other hand, MBS
phosphorylation at Thr-641 was practically unchanged after
histamine stimulation, although Thr-799 phosphorylation of
MBS increased slightly (Figures 3A and 3B). Phosphorylation
levels of Thr-641 and Thr-799 on MBS and Thr-38 on CPI17
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Figure 4 Specificity of the inhibitors against PKC and Rho kinase
(A) Effect of Y27632 and GF109203x on Rho kinase. MBS was phosphorylated by Rho kinase
in the buffer described in the Experimental section, except that [c-32P]ATP was used as a
substrate in the absence or presence of various concentrations of Y27632 or GF109203x.
Phosphorylated MBS was subjected to SDS/PAGE, followed by autoradiography. (B) Effect of
Y27632 on PKCa and e. CPI17 was phosphorylated by PKCa or e in the buffer described in
the Experimental section, except that [c-32P]ATP was used in the presence of various amounts
of Y27632. Phosphorylated CPI17 was subjected to SDS/PAGE, followed by autoradiography.
MLC (0.2 mg/ml) was also phosphorylated by PKCa or e in the presence of 30 mM Tris/HCl,
pH 7.5, 2 mM MgCl2, 50 mM NaCl, 0.2 mM CaCl2, 1 mM DTT, 1 lM microcystin-LR,
50 ng/ml PDBu, 0.1 mg/ml phosphatidylserine, 3 lg/ml PKC and 0.1 mM [c-32P]ATP
at 25 °C for 30 min.
after histamine stimulation, estimated from the relationship
between the signal strength of the Western blot and the protein
amount loaded shown in Figures 1(A) and 1(B), were 62.5‡8.9%
(nfl 9), 45.9‡3.8% (nfl 7) and 65.0‡5.8% (nfl 10), respect-
ively. The time course of the increase in CPI17 phosphorylation
was closely correlated with the increase in MLC phosphoryl-
ation (Figures 3C and 3D), suggesting that the histamine-induced
Ca#+-independent increase in MLC phosphorylation is due to the
CPI17 phosphorylation-induced inhibition of MLCP.
Figure 5 ET-1-induced activation of the contraction of an a-toxin-permeabilized strip of rabbit femoral artery
(A) Representative trace of ET-1-induced activation of contraction at constant Ca2+ in a-toxin-permeabilized rabbit femoral artery. ET-1 (100 nM) and 10 lM GTP were added at the steady state
of the contraction at pCa 7. (B) Effect of the ET-1 on the force of the a-toxin-permeabilized strip of rabbit femoral artery at pCa 7. The grey and black bars indicate Ca2+ (pCa 7)-induced contraction
and ET-1-induced sensitization, respectively. Values are means‡S.E.M. from four independent experiments and expressed as percentages of the maximum contraction obtained at pCa 5. (C) Change
in the phosphorylation of MLC, MBS and CPI17 during the ET-1-induced contraction of the a-toxin-permeabilized rabbit femoral artery. Smooth muscle strips were incubated for 5 min in Ca2+
solution (pCa 7), then stimulated by 100 nM ET-1. Smooth muscle strips were homogenized and subjected to Western blot using antibodies against pThr-641 of MBS, pThr-799 of MBS,
MBS, pThr-38 of CPI17, CPI17, pSer-19 of MLC and MLC.
It has been suggested that the Rho}Rho kinase pathway
and}or heterotrimeric G-protein}PKC pathway are involved in
the agonist-induced Ca#+-independent activation of smooth
muscle contraction [13,14,19–21,23]. To clarify the pathways
responsible for the regulation of MLCP modulators, a Rho
kinase-specific inhibitor and a PKC-specific inhibitor were tested
for their effect on Ca#+-independent contraction and
phosphorylation ofMLCPmodulators. Histamine-induced Ca#+-
independent activation of force was significantly diminished by
10 lM Y27632, a Rho kinase-specific inhibitor (Figure 2),
suggesting that Rho}Rho kinase cascade is involved in the Ca#+-
independent activation of force. The addition of guanosine 5«-[b-
thio]diphosphate (GDP[b-S]) further diminished the contraction
to the level similar to that before addition of histamine.
Consistently, the phosphorylation of MLC in the fibre was
significantly diminished by Y27632 treatment (Figures 3A and
3B). Phosphorylation of CPI17 was also markedly attenuated by
Y27632 (Figures 3A and 3B). We checked whether Y27632 can
inhibit PKCs, since it has been recently reported that Y27632
can inhibit the proteolytic fragment of PKCd [36]. Neither PKCa
nor PKCe was inhibited by Y27632 up to 100 lM (Figure 4B).
The results indicate that Rho kinase plays a role in histamine-
induced Ca#+-independent activation of a-toxin-permeabilized
smooth muscle, and that Rho kinase is involved in CPI17
phosphorylation at Thr-38. This is consistent with the recent
report that Rho kinase can phosphorylate CPI17 in itro [37].
It has been shown that Rho kinase phosphorylates MBS at
two sites in itro, Thr-641 and Thr-799, and that phosphorylation
at the former site but not the latter decreases the MLCP enzymic
activity in itro [28]. Thr-799 phosphorylation of MBS, a Rho
kinase-specific phosphorylation site, was decreased by Y27632
(Figures 3A and 3B), and this suggests that Rho kinase cascade
is activated by histamine stimulation. However, the
phosphorylation at Thr-641, a site responsible for the inhibition
of MLCP, was changed by neither histamine stimulation nor
Y27632 in smooth muscle fibre, indicating that MBS
phosphorylation at Thr-641 is not significantly influenced by
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Figure 6 Change in the phosphorylation of MLC, MBS and CPI17 during phorbol ester-induced contraction of a-toxin-permeabilized strips of rabbit femoral
artery
(A) Representative trace of PDBu-induced activation of contraction at pCa 7. PDBu (100 nM) was added at the steady state of the contraction at pCa 7 in the absence (left trace) and presence
of 10 lM Y27632 (middle trace) or 5 lM GF109203x (right trace). Arteries were pretreated with inhibitors for 5 min prior to the addition of PDBu. (B) Changes in the phosphorylation of MLC,
MBS and CPI17 during the PDBu-induced contraction. Smooth muscle strips were incubated for 5 min in pCa 7, then stimulated for 15 min by 100 nM PDBu in the absence or presence of 10 lM
Y27632 or 5 lM GF109203x. Smooth muscle strips were homogenized and subjected to Western blot using antibodies against pThr-641 of MBS, pThr-799 of MBS, MBS, pThr-38 of CPI17,
CPI17, pSer-19 of MLC and MLC. (C) Effect of Y27632 on the PDBu-induced changes in force development and phosphorylation of MBS, CPI17 and MLC. Inhibitors were applied 5 min before
the addition of PDBu. White, black and grey bars indicate levels of phosphorylation or contractions induced by Ca2+ alone (pCa 7), Ca2+ and PDBu, and PDBu at pCa 7 in the presence of Y27632,
respectively. Relative levels of phosphorylation are indicated as a percentage of the value obtained after PDBu stimulation. Values of force are indicated as percentages of the force at pCa 5.
All data are means‡S.E.M. from more than four independent experiments. *P ! 0.05, **P ! 0.01, ***P ! 0.001.
Rho kinase cascade (Figures 3A and 3B). Similar effects were
observed for treatment with GF109203x, a PKC-specific inhibitor
(Figures 2 and 3). To assure the specificity of GF109203x, the
inhibitory effects of the inhibitors were tested against MBS
phosphorylation by Rho kinase (Figure 4). While Y27632
potently inhibited Rho kinase and the activity was almost
completely inhibited at 10 lM, GF109203x showed little in-
hibitory activity against Rho kinase. Therefore, the change in the
phosphorylation level of the proteins tested in the fibre should be
attributed to PKC but not Rho kinase. GF109203x significantly
inhibited the histamine-induced activation of contraction (Figure
2) and MLC phosphorylation (Figures 3A and 3B). While
CPI17 phosphorylation was decreased by GF109203x, MBS
phosphorylation at Thr-641 was unchanged by GF109203x.
These results suggest that PKC pathway is also involved in the
Ca#+-independent activation of contraction and the regulation of
CPI17 phosphorylation, an MLCP modulator. The results also
suggest that CPI17 phosphorylation is predominantly responsible
for the regulation of MLCP and, therefore, the increase in MLC
phosphorylation during histamine stimulation. It is interesting
that the PKC inhibitor, GF109203x, diminished the
phosphorylation at Thr-799 of MBS in the fibre. Because Thr-
799 cannot be phosphorylated by PKC in itro, and GF109203x
does not inhibit Rho kinase (Figure 4), the results suggest that
PKC influences the Rho kinase pathway.
ET-1 also induced a Ca#+-independent contraction of the
permeabilized smooth muscle strips (Figure 5). Consistently,
MLC phosphorylation was significantly increased by ET-1
stimulation at constant [Ca#+]. During ET-1-induced contraction,
CPI17 phosphorylation at Thr-38 significantly increased while
MBS phosphorylation at Thr-641 was unchanged. On the other
hand, MBS phosphorylation at Thr-799 increased upon ET-1
stimulation. These results suggest that during ET-1 stimulation
the phosphorylation of CPI17 increases. This is reflected by the
increase in Ca#+-independent MLC phosphorylation, whereas
the phosphorylation of MBS is unchanged. This result suggests
that CPI17 phosphorylation plays a more significant role in the
regulation of MLCP than does MBS phosphorylation, thus
affecting MLC phosphorylation in smooth muscle strips. Since
the phosphorylation of MBS at Thr-799 increased upon ET-1
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Figure 7 Effect of GTP[S] on the change in the phosphorylation of MLC,
MBS and CPI17 in a-toxin-permeabilized strips of rabbit femoral artery
(A) Representative Western blot analysis of phospho-MBS, CPI17 and MLC during the GTP[S]
(GTPcS)-induced contraction in the absence and presence of 10 lM Y27632 or 5 lM
GF109203x. Smooth muscle strips were incubated for 5 min in pCa 7, then stimulated for
10 min with 10 lM GTP[S] in the absence or presence of 10 lM Y27632 or 5 lM
GF109203x. Smooth muscle strips were homogenized and subjected to Western blot using anti-
pThr-641, anti-pThr-799, anti-pThr-38 and anti-pMLC, respectively. (B) Effect of Y27632 and
GF109203x on the GTP[S]-induced changes in the phosphorylation of MBS, CPI17 and MLC.
Inhibitors were applied 5 min before the addition of GTP[S]. White, black, grey and hatched bars
indicate the phosphorylation levels induced by pCa 7 alone, GTP[S] at pCa 7, GTP[S] at pCa
7 in the presence of 10 lM Y27632, and GTP[S] at pCa 7 in the presence of 5 lM GF109203x,
respectively. Relative levels of phosphorylation are indicated as a percentage of the value
obtained after GTP[S] stimulation. All data are means‡S.E.M. from more than four independent
experiments. *P ! 0.05, ***P ! 0.001.
stimulation, it is anticipated that ET-1 can activate the Rho}Rho
kinase cascade, whereas Thr-641 phosphorylation of MBS re-
mains unchanged.
The above results suggest that PKC signalling plays a role in
the Ca#+-independent increase in MLC phosphorylation and the
contraction of smooth muscle, and that CPI17 phosphorylation
is involved in the PKC-induced activation of contraction. We
therefore examined the effect of the activation of PKC on CPI17
phosphorylation and MLC phosphorylation more directly. Fig-
ure 6 shows the effect of PDBu on force and the phosphorylation
of MLC as well as MLCP modulators. PDBu increased force at
constant free [Ca#+] (pCa 7) and the increase in MLC
phosphorylation at Ser-19. During the PDBu-induced Ca#+-
independent increase in force, CPI17 phosphorylation signifi-
cantly increased. However, no significant increase in MBS
phosphorylation was observed for Thr-641 site. Interestingly,
PDBu increased the phosphorylation of MBS at Thr-799 and
this increase in the phosphorylation at Thr-799 was inhibited by
Y27632. In addition, not only GF109203x but also Y23632
significantly diminished PDBu-induced activation of force de-
velopment and MLC phosphorylation. CPI17 phosphorylation
was also significantly attenuated by both inhibitors, although the
extent of inhibition by Y27632 was less than by GF109203x
(Figure 6). In contrast, MBS phosphorylation at Thr-641 was
not affected by these inhibitors. The results further support the
idea that CPI17 phosphorylation, but not MBS phosphorylation
at Thr-641, is predominantly responsible for the regulation of
MLCP upon external stimuli of smooth muscle contraction. It
should be noted that the phosphorylation of MBS at Thr-799
was significantly reduced by Y27632. The results suggest that
PKC pathway influences the Rho kinase activity in smooth
muscle fibre, since PDBu does not directly activate Rho}Rho
kinase and PKC cannot directly phosphorylate MBS at Thr-799.
The results also support the notion that both PKC and Rho
kinase contribute to the phosphorylation of CPI17.
It is known that GTP[S] activates both the membrane-
associated heterotrimeric G-protein cascade and the small
G-protein cascade and, therefore, most prominently activates
Ca#+-independent contraction of smooth muscle. Actually,
GTP[S] at pCa 7 induced 66.5‡4.2% of maximum contraction
obtained at pCa 5, higher than the histamine- or PDBu-induced
Ca#+-independent activation at pCa 7 (results not shown). As
shown in Figure 7, even in GTP[S]-induced stimulation, MBS
phosphorylation at Thr-641 did not change. This result suggests
that MBS phosphorylation at Thr-641 does not significantly
change in smooth muscle fibre even with GTP[S], a most potent
stimulant. Consistently, neither Y27632 nor GF109203x changed
the Thr-641 phosphorylation of MBS. In contrast, MLC and
CPI17 phosphorylation markedly increased by GTP[S] stimu-
lation, and the both inhibitors diminished the increase in the
phosphorylation of MLC and CPI17 (Figure 7). All the above
results showed that the phosphorylation of MBS at Thr-641 is
not changed during stimulation by various agonists that trigger
the Ca#+-independent activation of MLC phosphorylation and
muscle contraction.
Agonist-induced change in the phosphorylation of MBS and CPI17
in intact smooth muscle strips
Figure 8 shows histamine-induced contraction of intact rabbit
femoral artery. The addition of histamine promptly increased
force. Phosphorylation ofMLC was significantly increased within
30 s of histamine stimulation and stayed constant (Figures 8B
and 8C). As shown in Figure 8(B), CPI17 phosphorylation at
Thr-38 was undetectable before stimulation and markedly in-
creased upon histamine stimulation with similar kinetics to the
increase in MLC phosphorylation (Figure 8C). The phosphoryl-
ation of CPI17 at Thr-38 reached a maximum in 30 s of histamine
stimulation and stayed constant. On the other hand, a significant
level of MBS phosphorylation was detected at both Thr-641 and
Thr-799 under resting conditions (Figure 8B). Histamine stimu-
lation hardly changed the phosphorylation of MBS at Thr-641.
Removal of histamine immediately diminished force that is
accompanied by a decrease in MLC phosphorylation (Figure 8).
During the relaxation CPI17 phosphorylation significantly
decreased, whereas the phosphorylation of MBS at Thr-641 was
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Figure 8 Agonist-induced change in the phosphorylation of MLC, MBS and CPI17 in intact rabbit femoral artery
(A) Representative trace of histamine and ET-1-induced contraction of intact rabbit femoral artery. Smooth muscle strips were stimulated for 3 min in the presence of 10 lM histamine (left trace)
or 100 nM ET-1 (right trace). After stimulation, agonists were washed out with normal PSS. ET-1-induced contraction was irreversible by washing out, presumably due to the incomplete dissociation
of ET-1 from its receptor, whereas histamine was successfully washed out. (B) Changes in the phosphorylation of MLC, MBS and CPI17 during the histamine- or ET-1-induced contraction of intact
rabbit femoral artery. Smooth muscle strips were incubated for various durations in the presence of 10 lM histamine or 100 nM ET-1. Smooth muscle strips were homogenized and subjected
to Western blot using antibodies against pThr-641 of MBS, pThr-799 of MBS, MBS, pThr-38 of CPI17, CPI17, pSer-19 of MLC and MLC. Strips before stimulation (time 0) and washed out by
PSS (w/o) after histamine stimulation were also examined. (C) Temporal changes in the phosphorylation of CPI17 and MLC during histamine-induced contraction in intact rabbit femoral artery.
Relative phosphorylation levels of CPI17 and MLC are indicated as ratios (anti-pThr-38/anti-CPI17 and anti-pMLC/anti-MLC, respectively) of the bands in Western blot. Each value represents the
mean‡S.E.M. from more than three independent experiments and are percentages of the values obtained at 3 min after histamine stimulation.
virtually unchanged. These results clearly indicate that while
CPI17 phosphorylation significantly changes during the
contraction–relaxation cycle after histamine stimulation in intact
vascular smooth muscle, MBS phosphorylation at Thr-641 does
not change significantly during the contractile response of smooth
muscle. On the other hand, Thr-799 phosphorylation increased
upon histamine stimulation, suggesting that the Rho}Rho kinase
system was activated upon stimulation.
It is known that ET-1 produced by endothelial cells in blood
vessels is an important natural agonist for vascular smooth
muscle contraction [38]. ET-1 initiated the contraction of intact
femoral arterial smooth muscle strips (Figure 8). MLC
phosphorylation increased upon ET-1 stimulation along with
the increase in force. ET-1 stimulation also enhanced the
phosphorylation of CPI17. The phosphorylation level reached a
maximum within 1 min and stayed at a high level, which
correlates with the high MLC phosphorylation level and force.
In contrast, MBS phosphorylation was not significantly changed
by ET-1 stimulation at Thr-641 (Figure 8). The results are similar
to those for histamine stimulation, and indicate that vaso-
constrictor agonist stimulation changes CPI17 phosphorylation,
but not MBS at its inhibitory site, in intact vascular smooth
muscle. Washing out the strip with normal PSS could not reverse
ET-1-induced contraction, presumably due to the incomplete
dissociation of ET-1 from its receptor. Phosphorylation of CPI17
and MLC remained at similar levels to those during contraction
(results not shown).
DISCUSSION
There are two major factors regulating MLCP. CPI17, a MLCP-
specific inhibitor, requires phosphorylation at Thr-38 for its
inhibitory activity. PKC phosphorylates CPI17 in itro and it has
been shown that Rho kinase can also phosphorylate CPI17 in
itro [37]. Therefore, PKC and}or Rho kinase cascades may
regulate CPI17 activity, thus controlling MLCP activity (Figure
9). A second regulator is MBS, a myosin-binding subunit
of MLCP. It has been shown that MBS phosphorylation by
Rho kinase at Thr-641 decreases MLCP holoenzyme activity
in itro [28] (Figure 9). A key issue is whether phosphorylation
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Figure 9 Diagram of the agonist-induced contraction of smooth muscle
Upon the stimulation of specific receptor by vasoconstrictors, both PKC- and Rho kinase-
mediated pathways are activated. The PKC pathway may influence the upstream of Rho/Rho
kinase pathway via RhoGDI phosphorylation and its dissociation from RhoA. Both Rho kinase
and PKC phosphorylate CPI17 thus causing the inhibition of MLCP. The phosphorylation of
MBS at its inhibitory site (Thr-641) has a minimal effect on the regulation of MLCP. Rho kinase
might phosphorylate myosin, thus activating the contractile machinery directly. PLC,
phospholipase C ; PIP2, PtdIns(4,5)P2 ; DG, diacylglycerol ; IP3, Ins(1,4,5)P3 ; CaM, calmodulin ;
M20, small non-catalytic subunit ; SR, sarcoplasmic reticulum ; PP1, protein phosphatase
type-1.
of CPI17 and MBS are correlated with the change in MLC
phosphorylation.
The present study addressed this question using
phosphorylation-site-specific antibodies for Thr-38 of CPI17,
Thr-641 and Thr-799 of MBS, and Ser-19 of MLC as probes.
This approach enables us to monitor the change in the
phosphorylation at the functionally important specific sites of
the target proteins in smoothmuscle fibres. Since the conventional
method using radioactive phosphate incorporation only reports
the overall phosphorylation level of the proteins, the present
approach is particularly powerful for the proteins phosphorylated
at multiple sites. This is particularly important for MBS that is
phosphorylated at two or more sites [39], and MLC that can
be phosphorylated at Ser-1}Ser-2 and Thr-9 [40] in addition to
Ser-19 and Thr-18.
A critical finding of this study is that while CPI17
phosphorylation markedly increased after vasoconstrictor
agonist, such as histamine and ET-1, MBS phosphorylation at
Thr-641 hardly changed. The results were consistently obtained
for both intact and permeabilized fibres. Furthermore, while
Y27632, a Rho kinase inhibitor, and GF109203x, a PKC
inhibitor, markedly diminished the agonist-induced force acti-
vation in permeabilized fibre, these inhibitors did not decrease
MBS phosphorylation at Thr-641, the site responsible for the
inhibition of MLCP. These results indicate that MBS
phosphorylation does not play a significant role in a mechanism
for MLCP regulation, at least in the regulation of smooth muscle
contraction. On the other hand, CPI17 phosphorylation
increased promptly after agonist stimulation. The importance of
CPI17 in the Ca#+ sensitization mechanism has been reported.
Kitazawa et al. [15] showed that the addition of the CPI17 with
PKC to permeabilized smooth muscle strips results in the
activation of force at a constant [Ca#+], suggesting that CPI17
plays a role in a Ca#+-sensitization mechanism in smooth muscle.
Quite recently, it was shown that the phosphorylation of CPI17
in smooth muscle fibre is significantly elevated at the peak force
after agonist stimulation compared with that in the resting state
[18].
The present results are consistent with earlier reports and
further revealed that the kinetics of the increase in CPI17
phosphorylation are fast and that the time course of the increase
in MLC phosphorylation after agonist stimulation is closely
correlated with the increase in CPI17 phosphorylation at Thr-38.
The results further suggest that CPI17 phosphorylation and,
therefore, down-regulation of MLCP, contribute to the agonist-
induced initial increase in MLC phosphorylation in smooth
muscle, in addition to the more prolonged sustained phase of
MLC phosphorylation. Recently, Miyazaki et al. [41] reported
that the Rho}Rho kinase pathway predominantly contributes to
the increase in myosin phosphorylation near the plasma mem-
brane, while the Ca#+}MLCK pathway phosphorylates through-
out the cytoplasm of smooth muscle cells. It is thought that
CPI17 is a soluble protein that is present throughout cytosol. The
cytosolic proteins move in cytosol by diffusion. When CPI17 is
phosphorylated by the activated PKC or Rho kinase at the
plasma membrane, it is plausible that the phosphorylated CPI17
concentration would be higher near the membrane because the
phosphorylated CPI17 can be dephosphorylated with time during
the diffusion process, thus contributing to the increase in MLC
phosphorylation near the plasma membrane by decreasing
MLCP activity.
The increase in MBS phosphorylation by GTP[S] in
permeabilized smooth muscle strips [29] and cultured smooth
muscle cells [30] has been studied previously by monitoring the
incorporation of radiolabelled phosphate into MBS. It was
reported that the phosphorylation of MBS was increased after
agonist stimulation [29,30]. There is an apparent discrepancy
between these previous reports and the present study. The
previous method of using radioactive ATP monitors the addition
of the phosphorylation at MBS, but not the absolute level of
phosphorylation. For this reason, the extent of phosphorylation
in the resting state cannot be detected. The approach utilized in
the present study enables us to determine the extent of
MBS phosphorylation in the resting state, hence the difference
in MBS phosphorylation between the resting level and the
post-stimulation level. We found a significant level of MBS phos-
phorylation in the resting state. The estimated MBS phosphoryl-
ation level at Thr-641 in the resting state was approx. 60%.
Another critical issue is that MBS is phosphorylated at multiple
sites, but Thr-641 is the only site responsible for inhibition of the
holoenzyme phosphatase activity [28]. The method used in
previous studies was the incorporation of radioactive phosphate
into MBS [29,30], and therefore only the overall change in
phosphorylation at multiple sites of MBS could be observed, not
the change in phosphorylation of MBS at specific sites, i.e. Thr-
641. The present approach enables us to determine the change in
the phosphorylation of MBS at specific sites, i.e. Thr-641 and
Thr-799. Actually, our results showed that the phosphorylation
at Thr-799 of MBS changed with GTP[S] as well as with agonists.
Therefore, the overall extent of MBS phosphorylation is in-
creased in the present study by GTP[S] stimulation. This is con-
sistent with previous reports [29,30]. But, the important point
is that Thr-641, not Thr-799, is the site responsible for phos-
phatase inhibition. The present results showed that the significant
level of phosphorylation at Thr-641 is present at rest that
does not significantly change after agonist stimulation. There
is a possibility that Thr-641 phosphorylation may increase in a
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distinct part of the cell and decrease in another compartment
after agonist stimulation, which would make the total level of
phosphorylation detected by phospho-specific antibody un-
changed. The answer to this requires further study.
Nagumo et al. [30] measured MLCP activity of cultured
smooth muscle cells in the presence and absence of GTP[S]. Cells
were lysed and then MLCP was immunoprecipitated with
antibodies against MBS. It was found that MLCP activity was
decreased by approx. 50% with GTP[S] treatment. The present
results do not agree with the result by Nagumo et al. [30], since
GTP[S] treatment of the fibre did not change Thr-641
phosphorylation of MBS. One possible explanation for this
apparent discrepancy is that the immunoprecipitated MLCP
may contain CPI17, thus the phosphatase activity is changed by
GTP[S]-induced phosphorylation of CPI17, since CPI17 can be
co-immunoprecipitated with MLCP [42].
It has been thought that fast transient contraction after agonist
stimulation is due to Ca#+ mobilization. The resulting activation
of the calmodulin}MLCK pathway for MLC phosphorylation
and the down-regulation of MLCP then contributes to the
increase in MLC phosphorylation during the prolonged phase
after stimulation. However, the present study demonstrates that
the increase in CPI17 phosphorylation at Thr-38 eliciting the
down-regulation of MLCP is not much slower than the initial
increase in MLC phosphorylation after histamine stimulation.
Therefore, it is anticipated that MLCP down-regulation by
CPI17 phosphorylation plays a role in the increase in MLC
phosphorylation after agonist stimulation for both the transient
phase and the prolonged phase of contraction. However, it
would play a more significant role in the latter phase when Ca#+-
dependent activation signalling has ceased.
A question is the identity of CPI17 kinase in smooth muscle
fibre. Both Y27632, a Rho kinase-specific inhibitor, and
GF109203x, a PKC inhibitor, markedly attenuated CPI17
phosphorylation at Thr-38. The results suggest that both Rho
kinase and PKC contribute to the phosphorylation of CPI17 in
io (Figure 9). This is consistent with in itro results that both
PKC and Rho kinase can phosphorylate CPI17 at Thr-38 [16,37].
The protein kinase that phosphorylates MBS in io is complex.
It has been thought that the predominant protein kinase that
phosphorylates MBS is Rho kinase [27]. While Thr-641 of MBS
is not phosphorylated during the agonist-induced stimulation of
smooth muscle, the results indicate that agonist stimulation
activated the Rho}Rho kinase pathway because phosphorylation
of the Rho kinase-specific phosphorylation site, Thr-799 of
MBS, increased by agonist stimulation and the Rho kinase
inhibitor reversed the agonist-induced increase in Thr-799 phos-
phorylation. Our results also indicate that the increase in the
phosphorylation of Thr-799 on MBS by histamine stimulation is
mediated by Rho kinase because of its sensitivity to a Rho kinase
inhibitor ; however, GTP[S] may activate other kinases which
can phosphorylate Thr-799 on MBS since the increase in the
phosphorylation of Thr-799 by GTP[S] was only partially in-
hibited by Y27632 (Figure 7). Nevertheless, Thr-641 phosphoryl-
ation, another Rho kinase phosphorylation site of MBS in itro,
was changed neither by agonist stimulation nor by GTP[S]
stimulation. Moreover, a significant level of Thr-641 phos-
phorylation is observed under resting conditions. These results
suggest that Thr-641 can be phosphorylated by protein kinases
other than Rho kinase, and Rho kinase does not readily phos-
phorylate MBS in response to agonist stimulation in io, pre-
sumably because the Thr-641 is already phosphorylated by other
kinases in the resting state, while the phosphorylation level of
Thr-799 under resting conditions is lower than Thr-641 and
can be increased by Rho kinase upon stimulation. Recently,
MacDonald et al. [43] reported that a zipper-interacting pro-
tein kinase (‘ZIP kinase ’) fragment can associate with MBS
and utilize MBS as a substrate. It was also reported that integrin-
linked kinase can phosphorylate MBS at Thr-641 in itro,
although Thr-641 is not the preferred site [44]. Further studies
are required to identify the protein kinase responsible for the
phosphorylation of MBS at Thr-641 in io. While this manu-
script was being prepared, Shin et al. [45] reported that
prostaglandin F
#
a increased MBS phosphorylation at Thr-641 in
ferret portal vein, although the change in CPI17 phosphorylation
was not determined. Therefore, MBS phosphorylation may
contribute to MLCP inactivation under certain types of smooth
muscle stimulation.
Since a significant level of Thr-641 phosphorylation is observed
in the resting state in both intact and permeabilized smooth
muscle, it is reasonable to assume that Thr-641 phosphorylation
is not subjected to a rapid phosphorylation–dephosphoryl-
ation cycle in io but that it is rather stable. Consistent with this
notion, we found that Thr-641 phosphorylation is resistant to
dephosphorylation by major protein phosphatases [46]. MBS
phosphorylation at Thr-641, hence the regulation of MLCP via
MBS, might function in slower cellular processes such as cell
migration or gene regulation.
An interesting observation is that GF109203x, a PKC-specific
inhibitor, markedly diminished the phosphorylation of MBS at
Thr-799, a Rho kinase-specific phosphorylation site (Figure 3).
PKC actually does not phosphorylate the Thr-799 site in itro
(results not shown) and GF109203x hardly inhibited Rho kinase
(Figure 4). Therefore, it is reasonable to assume that PKC is
involved in the activation pathway of Rho kinase. Consistent
with this notion, Y27632 inhibited MLC phosphorylation during
PDBu-induced stimulation (Figure 6). Since PDBu does not
directly activate Rho}Rho kinase, the results suggest that PKC
activated by PDBu stimulates the Rho}Rho kinase pathway.
Recently, it was reported [47] that PKC phosphorylates RhoGDI
(where ‘GDI’ is guanine nucleotide dissociation inhibitor), and
this is correlated with the increase in Rho activity, presumably
due to the change in the interaction between GDI and Rho.
The present finding is consistent with this report, although the
mechanism by which PKC modulates the Rho pathway (Figure
9) is not clear at this moment and further studies are required.
The present study demonstrates that the regulation of MLCP
during agonist-induced contraction in smooth muscle is primarily
mediated via CPI17 phosphorylation at Thr-38. Another path-
way of the regulation of MLCP, i.e. the phosphorylation of MBS
at Thr-641, would play a more important role in the regulation
of myosin light chain phosphorylation in non-muscle cell systems,
such as platelets [42] and cultured non-muscle cell lines [48].
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